Inhibrx Stock Investor Sentiment
| INBX Stock | USD 11.61 0.29 2.56% |
Slightly above 70 percent of all Inhibrx's investors are curious in acquiring. The analysis of the overall investor sentiment regarding Inhibrx suggests that a large number of traders are confidant. Inhibrx's investing sentiment can be driven by a variety of factors including economic data, Inhibrx's earnings reports, geopolitical events, and overall market trends.
Comfort Level 70
Interested
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Inhibrx's input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Inhibrx.
News SentimentNeutral | Hype SentimentBullish | Insider SentimentAcquiring |
Inhibrx Historical Sentiment
Although Inhibrx's investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Inhibrx, such as negative comments on social media and news outlets, may cause fear in the market and push Inhibrx's investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Inhibrx.
Inhibrx |
Inhibrx Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Inhibrx can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about Inhibrx that are available to investors today. That information is available publicly through Inhibrx media outlets and privately through word of mouth or via Inhibrx internal channels. However, regardless of the origin, that massive amount of Inhibrx data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Inhibrx news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Inhibrx relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Inhibrx's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Inhibrx alpha.
Inhibrx Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart for the Treatment of Colorectal Cancer | 01/21/2025 |
2 | Inhibrx Earns Market Perform Rating from JMP Securities | 01/24/2025 |
3 | Inhibrx Expected to Announce Earnings on Thursday - MarketBeat | 02/05/2025 |
4 | Disposition of 600 shares by Brendan Eckelman of Inhibrx at 24.2007 subject to Rule 16b-3 | 02/27/2025 |
5 | Disposition of 1130 shares by Brendan Eckelman of Inhibrx at 25.8947 subject to Rule 16b-3 | 03/10/2025 |
6 | Disposition of 26667 shares by Brendan Eckelman of Inhibrx at 23.3 subject to Rule 16b-3 | 03/13/2025 |
7 | Inhibrx Biosciences Inc Reports Q4 2024 Net Loss of 47. ... | 03/17/2025 |
8 | Inhibrx Releases Quarterly Earnings Results, Misses Expectations By 0.21 EPS | 03/18/2025 |
9 | Disposition of 19898 shares by Brendan Eckelman of Inhibrx at 33.63 subject to Rule 16b-3 | 03/26/2025 |
10 | Disposition of 90000 shares by Kayyem Jon Faiz of Inhibrx subject to Rule 16b-3 | 03/27/2025 |
11 | Insider Trading | 04/01/2025 |
Additional Tools for Inhibrx Stock Analysis
When running Inhibrx's price analysis, check to measure Inhibrx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibrx is operating at the current time. Most of Inhibrx's value examination focuses on studying past and present price action to predict the probability of Inhibrx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibrx's price. Additionally, you may evaluate how the addition of Inhibrx to your portfolios can decrease your overall portfolio volatility.